199 related articles for article (PubMed ID: 16184180)
21. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
22. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
24. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience.
Nageswara Rao AA; Kumar R; Altaf S; Gourde JA; Rodriguez V; Khan SP
J Pediatr Hematol Oncol; 2012 Mar; 34(2):96-100. PubMed ID: 22146532
[TBL] [Abstract][Full Text] [Related]
25. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
26. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Yang DH; Lee JJ; Kim YK; Kim HJ; Shin HJ; Chung JS; Cho GJ
Am J Hematol; 2008 Aug; 83(8):649-53. PubMed ID: 18528826
[TBL] [Abstract][Full Text] [Related]
27. [Clinical trial of antithymocyte globulin for prophylaxis of acute graft-versus-host disease in pediatric recipients of bone marrow transplantation from unrelated donors].
Yagasaki H; Kojima S; Inaba J; Kato K; Matsuyama T
Rinsho Ketsueki; 1999 May; 40(5):382-9. PubMed ID: 10390886
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
29. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
30. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
[TBL] [Abstract][Full Text] [Related]
31. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
32. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
33. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
34. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
von dem Borne PA; Starrenburg CW; Halkes SJ; Marijt WA; Fibbe WE; Falkenburg JH; Willemze R
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S27-9. PubMed ID: 19561408
[TBL] [Abstract][Full Text] [Related]
35. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
[TBL] [Abstract][Full Text] [Related]
36. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
Gupta V; Ball SE; Sage D; Ortin M; Freires M; Gordon-Smith EC; Marsh JC
Bone Marrow Transplant; 2005 Mar; 35(5):467-71. PubMed ID: 15665848
[TBL] [Abstract][Full Text] [Related]
37. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children.
Hale GA; Bowman LC; Rochester RJ; Benaim E; Heslop HE; Krance RA; Horwitz EM; Cunningham JM; Tong X; Srivastava DK; Handgretinger R; Jones DP
Biol Blood Marrow Transplant; 2005 Nov; 11(11):912-20. PubMed ID: 16275594
[TBL] [Abstract][Full Text] [Related]
38. Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.
Neumann T; Schneidewind L; Thiele T; Schulze M; Klenner AF; Busemann C; Pink D; Greinacher A; Dölken G; Krüger WH
J Cancer Res Clin Oncol; 2016 May; 142(5):1091-7. PubMed ID: 26779644
[TBL] [Abstract][Full Text] [Related]
39. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
40. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab.
Silveira FP; Husain S; Kwak EJ; Linden PK; Marcos A; Shapiro R; Fontes P; Marsh JW; de Vera M; Tom K; Thai N; Tan HP; Basu A; Soltys K; Paterson DL
Transpl Infect Dis; 2007 Mar; 9(1):22-7. PubMed ID: 17313467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
